Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-07-27
2004-05-18
Wessendorf, T. D. (Department: 1627)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S069100, C536S024100, C536S024300, C530S317000
Reexamination Certificate
active
06737241
ABSTRACT:
FIELD OF THE INVENTION
The technical field of this invention is methods for screening for transdominant effector peptides and RNA molecules selected inside living cells from randomized pools.
BACKGROUND OF THE INVENTION
Signaling pathways in cells often begin with an effector stimulus that leads to a phenotypically describable change in cellular physiology. Despite the key role intracellular signaling pathways play in disease pathogenesis, in most cases, little is understood about a signaling pathway other than the initial stimulus and the ultimate cellular response.
Historically, signal transduction has been analyzed by biochemistry or genetics. The biochemical approach dissects a pathway in a “stepping-stone” fashion: find a molecule that acts at, or is involved in, one end of the pathway, isolate assayable quantities and then try to determine the next molecule in the pathway, either upstream or downstream of the isolated one. The genetic approach is classically a “shot in the dark”: induce or derive mutants in a signaling pathway and map the locus by genetic crosses or complement the mutation with a cDNA library. Limitations of biochemical approaches include a reliance on a significant amount of pre-existing knowledge about the constituents under study and the need to carry such studies out in vitro, post-mortem. Limitations of purely genetic approaches include the need to first derive and then characterize the pathway before proceeding with identifying and cloning the gene.
Screening molecular libraries of chemical compounds for drugs that regulate signal systems has led to important discoveries of great clinical significance. Cyclosporin A (CsA) and FK506, for examples, were selected in standard pharmaceutical screens for inhibition of T-cell activation. It is noteworthy that while these two drugs bind completely different cellular proteins—cyclophilin and FK506 binding protein (FKBP), respectively, the effect of either drug is virtually the same—profound and specific suppression of T-cell activation, phenotypically observable in T cells as inhibition of mRNA production dependent on transcription factors such as NF-AT and NF-&kgr;B. Libraries of small peptides have also been successfully screened in vitro in assays for bioactivity. The literature is replete with examples of small peptides capable of modulating a wide variety of signaling pathways. For example, a peptide derived from the HIV-1 envelope protein has been shown to block the action of cellular calmodulin.
A major limitation of conventional in vitro screens is delivery. While only minute amounts of an agent may be necessary to modulate a particular cellular response, delivering such an amount to the requisite subcellular location necessitates exposing the target cell or system to relatively massive concentrations of the agent. The effect of such concentrations may well mask or preclude the targeted response.
Thus, it is an object of the present invention to provide methods and compositions for the effective introduction of random libraries into cells to screen for bioactive compounds.
Relevant Literature
Mann et al. (1983) Cell 33, 153-159, Pear et al. (1993) Proc. Natl. Acad. Sci. USA 9O(18):8392-6 and WO 94/19478 describe the BOSC and BING retroviral systems useful as delivery vectors for the disclosed methods.
Scott and Craig (1994) Current Opinion in Biotechnology 5.40-48 review random peptide libraries. Hupp et al. (1995) describe small peptides which activate the latent sequence-specific DNA binding function of p53. Palzkill et al. (1994) report the selection of functional signal cleavage sites from a library of random sequences introduced into TEM-1-lactamase.
SUMMARY OF THE INVENTION
The invention provides methods and compositions for screening for transdominant bioactive agents such as pharmaceuticals. The invention accesses molecules or targets within living cells and provides for the direct selection of those bioactive agents with desired phenotypic effects.
In one aspect of the invention, methods for screening for a transdominant bioactive agent capable of altering the phenotype of a cell are provided. The methods comprise the steps of a) introducing a molecular library of randomized candidate nucleic acids into a plurality of cells, wherein each of said nucleic acids comprises a different nucleotide sequence; b) screening the plurality of cells for a cell exhibiting an altered phenotype, wherein the altered phenotype is due to the presence of a transdominant bioactive agent. The methods may also include the steps of c) isolating the cell(s) exhibiting an altered phenotype, d) isolating a candidate nucleic acid from the cell(s).
The invention further provides methods for isolating a target molecule using either a candidate nucleic acid or the expression product of a candidate nucleic acid.
In an additional aspect, the candidate nucleic acids of the invention are linked to fusion partners.
In a further aspect, the invention provides methods for screening for a transdominant bioactive agent capable of altering the phenotype of a cell. The methods comprises the steps of a) introducing a molecular library of randomized candidate nucleic acids into a first plurality of cells, wherein each of the nucleic acids comprises a different nucleotide sequence; b) contacting the first plurality of cells with a second plurality of cells; and c) screening the second plurality of cells for a cell exhibiting an altered phenotype.
In an additional aspect, the present invention provides molecular libraries of retroviruses comprising different randomized nucleic acids, and cellular libraries containing the retroviral libraries.
REFERENCES:
patent: 4618578 (1986-10-01), Burke et al.
patent: 4980281 (1990-12-01), Housev et al.
patent: 5217889 (1993-06-01), Roninson et al.
patent: 5223408 (1993-06-01), Goeddel
patent: 5266464 (1993-11-01), Housev et al.
patent: 5283173 (1994-02-01), Fields et al.
patent: 5639595 (1997-06-01), Mirabelli et al.
patent: 5650489 (1997-07-01), Lam et al.
patent: 5688655 (1997-11-01), Housev et al.
patent: 5698396 (1997-12-01), Pfreundschuh
patent: 5723287 (1998-03-01), Russell
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5747334 (1998-05-01), Kav et al.
patent: 5763192 (1998-06-01), Kauffman et al.
patent: 5770434 (1998-06-01), Huse
patent: 5814476 (1998-09-01), Kauffman et al.
patent: 5817483 (1998-10-01), Kauffman et al.
patent: 5824514 (1998-10-01), Kauffman et al.
patent: 5840479 (1998-11-01), Little et al.
patent: 5877007 (1999-03-01), Housey et al.
patent: 5935823 (1999-08-01), Fowlkes et al.
patent: 5955275 (1999-09-01), Kamb
patent: 6153380 (2000-11-01), Nolan et al.
patent: 6194544 (2001-02-01), Huffman et al.
patent: 2001/0053523 (2001-12-01), Jeasen
patent: 0 334 301 (1989-09-01), None
patent: 0 383 620 (1990-08-01), None
patent: 0 557 897 (1993-09-01), None
patent: 86/05803 (1986-10-01), None
patent: 90/02809 (1990-03-01), None
patent: 91/17266 (1991-11-01), None
patent: 91/19818 (1991-12-01), None
patent: 92/05266 (1992-04-01), None
patent: 92/07071 (1992-04-01), None
patent: WO 93/03143 (1993-02-01), None
patent: 93/08278 (1993-04-01), None
patent: 93/23569 (1993-11-01), None
patent: 94/06920 (1994-03-01), None
patent: WO 94/18219 (1994-08-01), None
patent: 94/19478 (1994-09-01), None
patent: WO 94/20608 (1994-09-01), None
patent: WO 94/29469 (1994-12-01), None
patent: 95/04824 (1995-02-01), None
patent: WO 95/11998 (1995-05-01), None
patent: 95/16054 (1995-06-01), None
patent: 96/23899 (1996-08-01), None
patent: 96/38553 (1996-12-01), None
patent: 96/40987 (1996-12-01), None
patent: 00/05406 (2000-02-01), None
Rayner and Gonda, “A Simple and Efficient Procedure for Generating Stable Expression Libraries by cDNA Cloning in a Retroviral Vector,”Mol Cell Biol14(2):880-887 (Feb. 1994).
Gudkov et al., “Cloning mammalian genes by expression selection of genetic suppressor elements: Association of kinesin with drug resistance and cell immortalization,”Proc. Natl. Acad. Sci. USA91:3744-3748 (Apr. 1994).
Whiteway et al., “Dominant negative selection of heterologous genes: Isola
Bozicevic Field & Francis LLP
Diehl James J.
Rigel Pharmaceuticals Inc.
Sherwood Pamela J.
Wessendorf T. D.
LandOfFree
Methods for screening for transdominant intracellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for screening for transdominant intracellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for screening for transdominant intracellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3236813